14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.027 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Genetic characterization of Mycobacterium bovis BCG Mexico 1931 P. Orduña 1 , Y. López 1 , M. A. Cevallos 2 , S. Ponce de León 3 1 Universidad Nacional Autonoma de Mexico, D.F., Mexico, 2 Universidad Nacional Autonoma de Mexico, Cuernavaca, Mexico, 3 BIRMEX, D.F., Mexico Background: BCG vaccine is the only preventive measure against tuberculosis. At least two genomes from BCG, Pasteur and Japan, have been described. Evolutionary schemes establish by DU2 and other markers situated BCG Japan and Pasteur into group I and IV from genealogy of BCG vaccines, respectively, classified as early and late strains. Some BCG such as Mexico 1931 is not included in any comparative studies based on phenotypic, genotyping, immune response and drug resistance. Our aim was to characterize by full sequence BCG Mexico 1931 for using in the new develop vaccine. Methods: The sequence of BCG Mexico 1931 was performed with 2X pyrosequencing method. BCG Mexico 1931 genetic profile was performed by multiplex PCR and PFGE. The multiplex PCR was performed to detect RD and DU regions in strains. The reference BCG strains used in this study were Pasteur 1173P2, Phipps, Tice and Danish 1331. Results: The circular chromosome at 99.8% coverage of BCG Mexico 1931 was 4 350 386-bp, its analyses confirm the RD1, RD2, nRD18 absence and the presence of duplication DU2 group IV described by multiplex PCR. The comparison of BCG Pasteur1173P2 genome sequence with BCG Mexico 1931 showed differences between strains, including the presence of RD14, SNPs and the absence of DU1. In addition, three new RD regions of 53, 655 and 2847 bp were uncovered. The comparison of profiles obtained by PCR multiplex showed that BCG Mexico 1931 profile was identical to BCG Phipps and Tice, with the lost of RD1, RD2, nRD18 and presence of DU2 group IV. PFGE was performed with AsnI/DraI enzymes, the analyses detected 18/12 fragments in BCG Danish 1331 and Mexico 1931, 17/12 in Pasteur 1173P2, 15/10 in Phipps and 14/10 in Tice, respectively. Interesting, the restriction pattern with AsnI showed the presence of 220kb fragment only in BCG Mexico, Tice and Phipps. Conclusion: The BCG Mexico 1931 showed a close relation with BCG Phipps and Tice, strains situated into group IV from genealogy of BCG vaccines. However, in diverse studies these strains shown differences on the induction of immune response.
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.028 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Pneumococcal vaccination - is hyporesponsiveness a problem? H. Lode RCMS, Berlin, Germany Background: Several studues in the past have demostrated that the pneumococcal polysaccharide vaccine (PPV 23) will induce hyporesponsiveness in vaccinated patients over a long time period. The duration of this effect and the impactv on a second vaccination with a conjugated vaccine (PCV 13) after at least 3 years is not known. Methods: To address these open questions we investigated 55 persons ( 30 males, age between 68 and 87 years), who had a first PPV 23 - vaccination 3 - 8 years before and received a second vaccination with PCV 13. Immediately before and 4 - 6 weeks after PCV 13 vaccination blood specimen were taken and antibodies to 13 individual poysaccharides( 1,3,4,5,6A,6B,7F,9V,14,18,19A,19F,25F) were determined by a validated enzyme-linked immunosorbent assay. Results: 3 - 8 years after PPV 23 vaccination antibody concentrations were low but in 11 out of 13 serotypes still above 1,0 g/ml (the assumed protection level for adults ); only serotypes 3 and 23F had mean concentrations (+/- SD) of 0,66+/- 0,38 g/ml and 0,57+/- 0.39 g/ml. 4 - 6 weeks after vaccination with PCV 13 all serotypes showed an significant increase in antibody concentrations; however, a great response variability between the different serotypes was measured with small antibody increases in serotype 3 and high concentrations in serotypes 4, 5,7F,19A and 19F.The tolerance of vaccination with PCV 13 was excellent. Conclusion: The results of this study demonstrate that a first PPV 23 vaccination has only limited impact on a second vaccination with a new conjugated pneumococcal vaccine(PVP13) 3 - 8 years later. Hyporesponsiveness was not a major problem in this study. However, these results have to be confirmed in a study with a greater number of elderly patients.
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216: When citing these abstracts please
Page 265: When citing these abstracts please
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?